Calyxt

Calyxt, Inc. is technology company. engages in delivering plant-based solutions. Its products include high oleic soybean oil, high fiber wheat, high oleic soybean meal, and low lignin alfalfa. The company was founded by Daniel F. Voytas and André Choulika on January 8, 2010 and is headquartered in Roseville, MN.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. It focuses on using gene editing to develop productivity traits in major agricultural crops such as Canola, Rice, Soybean, Corn and Wheat. The company was founded by Rory Riggs, Peter Beetham and Greg Gocal in 2010 and is headquartered in San Diego, CA.

Archer-Daniels-Midland Company

ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, announced today that it has contracted to sell all 2020 grain production of its high oleic soybean to ADM (NYSE: ADM), a global leader in human and animal nutrition and the world's premier agricultural origination and processing company headquartered in Chicago. The transaction is a key step in Calyxt's 2020 transition to an advanced go-to-market strategy focused on providing plant-based innovation

Calyxt Announces Sale of Entire 2020 Grain Production to ADM

Project delays and slower than anticipated growth contradicts CLXT's business model that claim a speedy development cycle using novel gene-editing technologies.

Calyxt To Exit Farming Operations And Focus On Seed Science

Calyxt (CLXT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Calyxt (CLXT) a New Strong Buy Stock

ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, today announced a research collaboration with NRGene® that includes the adoption of NRGene's cloud-based genomics platform to support key Calyxt's research projects. The genomics solutions are expected to allow for more comprehensive evaluations to accelerate trait discovery and breeding across multiple crops. Calyxt is leveraging its proprietary breeding techniques and TALEN® technology to optimiz

Calyxt Announces Collaboration with NRGene® to Advance its Product Pipeline

Calyxt, Inc.'s (CLXT) CEO Jim Blome on Q3 2020 Results - Earnings Call Transcript

ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, has reported its financial results for the third quarter ended September 30, 2020. Execution of commercial agreement with S&W Seed Company on IQ™ Alfalfa product, marking Calyxt's first trait license agreement: Based on long-term U.S. sales projections, the agreement could potentially generate more than $10M of license revenue over the life of the pending patent for the trait. The enhanced trai

Calyxt Reports Third Quarter 2020 Financial Results

S&W Seed

ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, announced today that it has agreed to commercial terms with S&W Seed Company (Nasdaq: SANW), a global agricultural company headquartered in Longmont, Colorado for the exclusive license of an improved quality alfalfa seed in the U.S. and other select geographies. This marks the company's first commercial trait license agreement and, based on U.S. sales projections, could potentially generate mor

Calyxt Announces Commercial Agreement with S&W Seed Company to Deliver Improved Quality Alfalfa

ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, will host a Virtual Analyst Day on Tuesday, November 17, 2020 at 4:00 p.m. Eastern time. The Virtual Analyst Day will be broadcasted via webcast, and include a review of the company's research and development pipeline and a business update from management, followed by a Q&A session with the sell-side analyst community. Agenda: Date: Tuesday, November 17, 2020 Presentation Time: 4:00 p.m. Easter

Calyxt to Host Virtual Analyst Day on Tuesday, November 17, 2020 at 4:00 p.m. Eastern Time

ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT) (the “Company”), a plant-based technology company, today announced the closing of its previously announced registered direct offering of 3,750,000 shares of the Company's common stock, at a purchase price of $4.00 per share. Cellectis S.A., the Company's majority shareholder, purchased 1,250,000 shares in the offering. H.C. Wainwright & Co. acted as the exclusive placement agent for the transaction. The gross proceeds to the Com

Calyxt Announces Closing of Registered Direct Offering of Common Stock

ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT) (the “Company”), a plant-based technology company, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 3,750,000 shares of the Company's common stock, at a purchase price of $4.00 per share, in a registered direct offering. Cellectis S.A., the Company's majority shareholder, subscribed to purchase 1,250,000 shares in the offering. The closing of the offering is exp

Calyxt Announces $15 Million Registered Direct Offering

ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, announced today that it has appointed Sarah Reiter as Vice President, Business Development. In this role, Ms. Reiter will drive new business opportunities at Calyxt to support the company’s recently announced go-to-market strategies. Ms. Reiter is a plant-based technology and agribusiness leader focused on establishing world-class partnerships and value chains that lead to the successful commercial

Calyxt Appoints Sarah Reiter as Vice President of Business Development

ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, will hold a conference call on Thursday, November 5, 2020 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2020. A press release detailing these results will be issued prior to the call. Calyxt Chief Executive Officer Jim Blome and Chief Financial Officer Bill Koschak will host the conference call, followed by a question and answer session. The conference c

Calyxt to Host Third Quarter 2020 Financial Results Conference Call on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time

ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc.

Calyxt to Present at Upcoming September Investor Conferences

Calyxt, Inc. (CLXT) CEO James Blome on Q2 2020 Results - Earnings Call Transcript

Calyxt Reports Second Quarter 2020 Financial Results

Calyxt to Present at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020

Calyxt to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020 at 8:00 a.m. Eastern Time

ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, announced the appointment of current board member Yves Ribeill, Ph.D., as Chairman. This appointment coincides with Dr. André Choulika's decision to wholly focus his energy on Cellectis’ clinical development activities, and thus, retiring as Chairman of Calyxt’s Board. Additionally, Calyxt’s Board of Directors appointed Laurent Arthaud (Cellectis Board member) as Director. These changes are effecti

Calyxt Announces Board Changes

B&G Foods

Inovio Pharmaceuticals

Medifast

Purple Innovation

U.S. consumer confidence gained in May and beat the expectations of economists polled by Dow Jones.

Here's How Americans Are Regaining Confidence: 5 Picks

Calyxt (CLXT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Calyxt (CLXT) Moves to Strong Buy: Rationale Behind the Upgrade

Calyxt's (CLXT) CEO Jim Blome on Q1 2020 Results - Earnings Call Transcript

Calyxt, Inc.'s (CLXT) CEO Jim Blome on Q4 2019 Results - Earnings Call Transcript

Precision Biosciences

Cellectis SA

Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.

These Gene-Editing Pioneers Are Making Bold Bets in Agriculture

Falling knives are companies whose share prices have declined more than 59% over the last 52 weeks.

Analysts Recommend These 2 Falling Knives

Calyxt, Inc.'s (CLXT) CEO Jim Blome on Q3 2019 Results - Earnings Call Transcript

News for Calyxt Stock (CLXT)